Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts and focused on developing injectable biologics that selectively engage disease-specific T cells. News about Cue Biopharma often centers on its Immuno-STAT platform, clinical data from its CUE-100 series programs, and progress in autoimmune disease and oncology.
Investors and followers of CUE stock can use this page to review company press releases and third-party coverage related to Cue Biopharma’s pipeline. Typical updates include clinical trial readouts for CUE-101 in HPV16+ head and neck cancer and CUE-102 in WT1-expressing tumors, as well as developments around CUE-401, the company’s lead autoimmune asset designed to promote regulatory T cell–mediated tolerance.
News flow also highlights Cue Biopharma’s strategic collaborations and corporate milestones. Examples include agreements with Boehringer Ingelheim for CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases, and a collaboration and license agreement with ImmunoScape to advance a Seed-and-Boost cell therapy approach for solid tumors using the CUE-100 series. Financial updates, such as quarterly results, collaboration revenue disclosures and public equity offerings under the company’s shelf registration statement, are also common topics.
By following this CUE news feed, readers can track regulatory interactions, investigator-sponsored trials, leadership transitions, licensing deals and financing activities that may influence Cue Biopharma’s development trajectory. Bookmark this page to quickly access the latest headlines and historical announcements related to Cue Biopharma and its Immuno-STAT-based biologics.
On June 15, 2020, Cue Biopharma announced progress in its Phase 1 trial of CUE-101 for HPV+ recurrent and metastatic head and neck squamous cell carcinoma. The trial has enrolled 13 patients, with ongoing data generation showing dose-proportional increases in drug exposure and evidence of selective T cell expansion. Preliminary results indicate clinical activity, with one patient experiencing stable disease after treatment. The drug has been well-tolerated, with primarily mild adverse events. Further patient enrollment at the 1.0 mg/kg dose is planned to refine CUE-101's therapeutic window.
Cue Biopharma, Inc. (CUE) provided a business update for Q1 2020, reporting collaboration revenue of $0.9 million, up from $0.4 million in Q1 2019. R&D expenses rose to $9.9 million due to ongoing clinical trials, including the CUE-101 mono-therapy and a collaboration with Merck on KEYTRUDA®. The company ended the quarter with a net loss of $12.8 million, slightly higher than the previous year. Cue Biopharma raised $34.3 million through an ATM offering in April, enhancing its cash position amidst pandemic challenges.
Cue Biopharma (CUE) announced a poster presentation at the AACR Virtual Annual Meeting II, showcasing pre-clinical data on its drug candidates CUE-102/A02 and CUE-102/A24 from the CUE-100 series. These Immuno-STATs™ selectively target Wilms’ tumor 1 (WT1) specific T cells for cancers like AML and breast cancer. The presentation, led by Dr. Saso Cemerski, will occur on June 22, 2020. The CUE-100 series aims to engage T cells directly in patients, potentially reducing toxicities seen in traditional therapies. Cue Biopharma is focused on transforming cancer treatment with its innovative approach.
Cue Biopharma (NASDAQ: CUE) has announced a research collaboration with Dr. Michael Dustin and the University of Oxford to explore the IL-2-based CUE-100 series Immuno-STAT biologics. This partnership aims to investigate molecular mechanisms of T cell activation and modulation related to cancer treatment. The findings are expected to enhance understanding of the mechanism of action of the lead asset, CUE-101, currently in clinical trials for head and neck cancer, potentially advancing the development of new therapies for solid and hematological cancers.
Cue Biopharma (NASDAQ: CUE) announced a conference call and webcast for a business update on May 19, 2020, at 4:30 p.m. EDT. The event will provide insights into the company’s platform and pipeline advancements, alongside strategic objectives and milestones. Cue Biopharma, headquartered in Cambridge, Massachusetts, specializes in engineering injectable biologics to selectively engage T cells to combat cancer and autoimmune diseases using its proprietary Immuno-STAT™ platform. Investors can access the live event via the company’s website.